Treatment with the aromatase inhibitor letrozole (Femara) can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy. The results of a study involving women originally in the placebo arm of an international trial of letrozole will appear in the Journal of Clinical Oncology and are receiving early online release.

More: continued here

This entry was posted on Saturday, March 15th, 2008 at 12:03 am and is filed under Breast Cancer. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.